Colorectal Surgery, a New Robotic Platform (Hugo Ras)

Launched by FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA · Jul 19, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new robotic surgery system called the Hugo Robotic Assisted Surgery (RAS) platform, which is designed to help surgeons perform colorectal surgeries more effectively. The goal is to see if this innovative technology is safe and effective for treating conditions like colon and rectal cancer, diverticulosis, and other colorectal issues. The trial is currently looking for participants aged 18 and older who are scheduled for planned colorectal surgeries using this new robotic system.

To be eligible for the study, participants should not have had emergency surgeries or prior laparoscopic (minimally invasive) or open surgeries for their condition. Individuals with severe cognitive issues that prevent them from understanding or agreeing to participate, as well as those in advanced cancer stages, are also excluded. If you join the trial, you can expect to undergo surgery using the Hugo robotic system, and researchers will monitor your recovery and outcomes to better understand how this technology can improve surgical care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pacientes intervenidos de forma programada de procedimientos en cirugía colorrectal abdominal (neoplasia de colon, neoplasia de recto, diverticulosis, resección intestinal, cirugía transanal mínimamente invasiva (TAMIS), con la plataforma robótica Hugo™ RAS, en régimen de protocolos de rehabilitación multimodal (protocolos ERAS) (ANEXO 2).
• • Edad mayor o igual a 18 años.
• Exclusion Criteria:
• • Pacientes intervenidos mediante abordaje inicial laparoscópico o abierto.
• • Resecciones colorrectales de carácter urgente.
• • Pacientes menores de 18 años.
• • Existencia de otros procesos quirúrgicos concomitantes.
• • Deterioro cognitivo severo que imposibilita la colaboración del paciente.
• • Pacientes diagnosticados en estadio IV oncológico.
• • Pacientes que rechacen participar